Study of level of netrin-1 in serum of patients with type 2 diabetic nephropathy
Abstract
Diabetic nephropathy is among the devastating outcomes of diabetes. An essential part of slowing its development is early detection. The goal was to determine the impact of netrin-1 on microalbuminuria and early detection of nephropathy type 2 DM. This trial was conducted on 120 patients divided equally into four groups: group (1) Healthy normal persons; group (2) patients with type 2 DM without albuminuria (albumin/creatinine ratio <30 mg/gm), group (3) patients with type 2 DM with microalbuminuria (albumin creatinine ratio 30–299 mg/gm), and group (4) patients with type 2 DM with overt proteinuria (albumin creatinine ratio ≥300 mg/gm). All participants were subjected to complete history taking, full clinical examination, routine labs, and Netrin-1 level. The highest level of Netrin-1 was found in group 4 (56.2±20.5), followed by group 3 (43.2±22.4), group 2 (36±13.4), and group 1 (33.2±10.8) (P-value <0.001). In addition, there was a significantly higher Netrin-1 level in diabetic nephropathy patients (49.7±22.3) than in patients without nephropathy (34.6±12.1) (P-value <0.001). Plasma netrin-1 level is significantly elevated in patients with diabetic nephropathy, whether micro or macro proteinuria, and there is a future hope for the possibility of using netrin 1 as an early predictor for the diagnosis of diabetic nephropathy.